AP gears up to promote generic drugs

Directive to stop issuing licences to drug companies based on their brand names may be implemented

November 09, 2012 11:40 am | Updated 11:40 am IST - HYDERABAD

In an attempt to promote generic drugs in the capital and elsewhere, the Drug Control Administration (DCA) authorities are getting ready to implement a Drugs Controller General of India (DCGI) directive to stop issuing licences to drug companies based on their brand names. Senior DCA authorities in Hyderabad said that they were waiting for an official communication from DCGI before they can start implementing it. The new DCGI directive has already come into force in Kerala, Tamil Nadu and Maharashtra. The directive has the potential to stop the practice of brand promotion of drugs, which is rampant and carried out by medical representatives. Many also fear that strict enforcement of the latest rules could also trigger large scale retrenchments and impact the livelihood of medical representatives.

In fact, associations representing the interests of pharmaceutical companies and medical representatives in Hyderabad maintained that their respective leaders in New Delhi are in talks with DCGI and Union Government authorities seeking relief from such a directive. The DCGI directive states that the DCA will not issue manufacturing licence to drug companies based on their brand names. The pharmaceutical companies who apply for license will have to submit the generic name of the drug and not as brands for manufacturing license. Senior DCA officials here are, however, confident of implementing the directive as the Union Government’s objective is to promote and make available the cheaper generic drugs. The government is making efforts to popularise generic drugs and directed its doctors to avoid recommending brand names of drugs in prescriptions.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.